10-K: INmune Bio Inc. Files 10-K Annual Report, Outlines Progress in Immunotherapy Development

INmune Bio Inc. released its 10-K annual report, detailing its financial status and advancements in its immunotherapy programs targeting cancer, Alzheimer's disease, and treatment-resistant depression.

Summary

• INmune Bio Inc. is a clinical-stage immunology company focused on developing therapies that reprogram the innate immune system to treat diseases.
• The company's two main platforms are a dominant-negative TNF platform (DN-TNF) and a Natural Killer (NK) cell priming platform (INKmune).
• The DN-TNF platform, which includes drugs like XPro and INB03, aims to neutralize soluble TNF (sTNF) without affecting transmembrane TNF (tmTNF), offering a unique approach to inflammation management.
• INKmune is designed to enhance the ability of a patient's own NK cells to target and eliminate cancer cells, particularly residual disease after other treatments.
• The company is focusing on developing XPro for Alzheimer's disease (AD) and treatment-resistant depression (TRD), with plans to explore its use in Duchenne muscular dystrophy (DMD) and cancer through partnerships.
• A Phase I trial of XPro in AD patients showed a decrease in neuroinflammation, leading to a global Phase II trial in early AD patients with biomarkers of inflammation.
• The company has also received funding from the National Institute of Mental Health (NIMH) for a Phase II trial of XPro in TRD.
• INKmune is currently in a Phase I/II trial for metastatic castrate-resistant prostate cancer (mCRPC), with initial patient enrollment completed in early 2024.
• The company reported a net loss of $30 million for 2023 and has an accumulated deficit of $121 million, raising concerns about its ability to continue as a going concern.
• As of December 31, 2023, the company had cash and cash equivalents of $35.8 million.
• The company is exploring various financing options, including equity and debt financing, government funding, and strategic alliances.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there is progress in clinical trials and novel technology, the financial situation and going concern warning are significant concerns. The company is in a high-risk, high-reward situation.

Positives

• The company's DN-TNF platform has a unique mechanism of action that may avoid side effects associated with non-selective TNF inhibitors.
• INKmune has shown promise in converting resting NK cells into tumor-killing memory-like NK cells.
• The company has completed a Phase I trial of XPro in AD, demonstrating a reduction in neuroinflammation.
• The company has secured funding from NIMH for a Phase II trial of XPro in TRD.
• The company has initiated a Phase I/II trial of INKmune in mCRPC.
• The company has a validated manufacturing process for CORDstrom, a clinical-grade mesenchymal stem cell product.
• The company has a two-pronged patent strategy to solidify existing IP and expand into related therapeutic areas.

Negatives

• The company has incurred significant losses and negative cash flows since inception.
• The company's ability to continue as a going concern is in doubt.
• The company has a substantial amount of debt.
• The company is significantly dependent on the success of its DN-TNF and NK cell priming platforms.
• The company faces intense competition in the markets targeted by its product candidates.
• The company has a limited operating history and has not yet commercialized any products.
• The company relies on third parties for manufacturing and clinical trials, which could lead to delays or failures.
• The company may not be able to obtain regulatory approval for its product candidates.
• The company may not be able to achieve market acceptance for its product candidates, even if approved.
• The company's stock price may be volatile.

Risks

• The company will require additional capital to finance its operations and may not be able to obtain it on acceptable terms.
• The company's ability to successfully engage with, and satisfactorily respond to, requests for information from the FDA in the future is a risk.
• The company has a substantial amount of debt, and may be unable to make required payments.
• The company is significantly dependent on the success of its DN-TNF and Natural Killer Cell Priming Platforms.
• The company needs to attract and retain highly skilled personnel and may be unable to effectively manage growth with limited resources.
• The biotechnology and immunotherapy industries are characterized by rapid technological developments and a high degree of competition.
• The company can provide no assurance that its clinical product candidates will obtain regulatory approval or that the results of clinical studies will be favorable.
• Drug discovery and development is a complex, time-consuming and expensive process with a high rate of failure.
• The company may face legal claims, which are expensive, and the company may not be able to afford the costs.
• The company relies upon patents to protect its technology and may be unable to protect its intellectual property rights.
• The price of the company's common stock may be volatile.
• A limited public trading market may cause volatility in the price of the company's common stock.
• The company's Rights Agreement contains anti-takeover provisions that could discourage, delay or prevent a change in control, which may cause the stock price to decline.
• The company's officers and Directors own the company that it licenses its INKmune patent from, which may create a conflict of interest.
• The company may be subject to federal regulations such as march-in rights, certain reporting requirements and a preference for U.S.-based companies due to government funding of intellectual property.
• The company's licensors may not properly maintain or enforce the intellectual property underlying the licenses, or may seek to terminate the licenses.
• The company may be unable to obtain or maintain sufficient insurance coverage at an acceptable cost or to otherwise protect against potential product liability claims.
• The company may experience delays or difficulties in the enrollment of patients in clinical trials.
• The company may be unable to obtain FDA approval of any proposed product brand names.
• The company may rely on orphan drug status to develop and commercialize its product candidates, but orphan drug designation, if obtained, may not confer marketing exclusivity or other expected commercial benefits as anticipated.
• The market opportunities for the company's product candidates may be smaller than the company believes they are.
• The company may fail to comply with regulatory requirements.
• The company may not be able to establish marketing and sales capabilities or enter into agreements with third parties to market and sell its product candidates.
• The company may request priority review for its product candidate in the future, but the FDA may not grant it.
• The company may be eligible for accelerated approval pathways, but may not be able to obtain such approval.
• The company may experience unforeseen events in connection with clinical trials of any of its product candidates, which could delay or prevent marketing approval.
• The company may not be able to manufacture a scalable quantity of its product for clinical trials or commercialization.
• The company may be liable for damages if it or its third-party manufacturers use hazardous and biological materials in a manner that causes injury or violates applicable law.
• The company may be subject to product liability lawsuits.
• The company may be subject to unfavorable pricing regulations, third-party payor reimbursement practices or healthcare reform initiatives.
• The company may be subject to cybersecurity incidents and other technological disruptions.
• The company's employees, principal investigators, consultants and commercial partners may engage in misconduct or other improper activities.
• The company may be exposed to risks related to currency exchange rates.
• Public health threats could have an adverse effect on the company's operations and financial results.
• Certain shares previously sold under the company's Sales Agreement with BTIG LLC may have been sold in violation of federal and state securities laws and may be subject to rescission rights and other penalties.

Future Outlook

The company expects to continue to incur significant losses for the foreseeable future as it continues its research and development of, and seeks regulatory approvals for, its product candidates. The company plans to pursue an efficient registration strategy using INB03 and XPro to improve the lives of patients with cancer and neurodegenerative diseases. The company also plans to pursue other indications in neurodegenerative diseases as resources become available. The company is actively seeking partners for its INB03, XPro and DMD programs.

Management Comments

• Management intends to pursue additional funding and implement its strategic plan to allow the opportunity for the Company to continue as a going concern.
• Management believes that INKmune represents a novel approach to cancer treatment.
• Management believes that XPro targets activated microglia and astrocytes of the brain that produce sTNF that promotes nerve cell loss, synaptic dysfunction and prevents myelin repair key elements in the development of dementia.
• Management believes that INKmune is best used to eliminate residual disease after the patient has completed other cancer therapies.

Industry Context

The report highlights the competitive landscape of the immunotherapy market, noting the rapid growth and focus on T-cell-based therapies. INmune Bio is positioning itself with its NK cell-based approach and DN-TNF platform, aiming to address unmet needs in cancer and neurodegenerative diseases. The company is also navigating the evolving regulatory landscape, including the impact of the Inflation Reduction Act on drug pricing.

Comparison to Industry Standards

• The company competes with established pharmaceutical and biotechnology companies, including Century Therapeutics, Immunity Bio, Nkarta, Fate Therapeutics, and Glycostem in the NK cell therapy space.
• The company also competes with companies in the personalized immuno-oncology business, such as Bluebird, Juno Therapeutics, Mustang Bio, Novartis, and Gilead, which are focused on T-cell activation strategies.
• The company competes with companies in the precision immune-oncology category, including Merck, GSK, BMS, and Roche, which are focused on anti-cancer antibody products and checkpoint inhibitors.
• The company's approach to targeting MUC4+ tumors with INB03 is unique, as there are no other companies developing a therapy to treat patients with MUC4+HER2+ tumors.
• The company's approach to targeting neuroinflammation with XPro is also unique, as there are few companies using an anti-inflammatory strategy for the treatment of Alzheimer's disease, including Denali Therapeutics, Alector, and Gliacure.
• The company's approach to using INKmune to target residual disease after debulking cancer therapies is also unique, as most other NK cell therapies focus on replacing or supplementing NK cells.

Legal Proceedings

• The company may be subject to claims for rescission by purchasers who purchased shares of common stock under the ATM program in July 2023.
• The company could become subject to enforcement actions and/or penalties and fines by federal authorities in connection with the ATM share sales.

Related Party Transactions

• The company paid UCL $573,000 and $586,000 in 2023 and 2022, respectively, for medical research.
• The company paid CTI $153,000 in 2022 pursuant to its former sublease agreement and $5,000 for research and development.
• The company paid AmplifyBio $77,000 and $230,000 in 2023 and 2022, respectively, for research and development.
• The company's officers and directors own Immune Ventures, LLC, from which the company licenses its INKmune patent.

Stakeholder Impact

• Shareholders face the risk of dilution and potential loss of investment due to the company's financial situation and need for additional capital.
• Employees face uncertainty due to the company's going concern status and potential need for restructuring.
• Patients may benefit from the company's novel therapies, but the development process is lengthy and uncertain.
• Creditors face the risk of non-payment due to the company's financial difficulties.
• Partners face the risk of delays or termination of collaborations due to the company's financial situation.

Next Steps

• Complete enrollment of 201 patients in the Phase II AD trial by mid-year.
• Obtain top line cognition data with EMACC six months after the last patient is enrolled in the Phase II AD trial.
• Obtain secondary end-points data from the Phase II AD trial 2-3 months after top line data.
• Hold an end-of-phase II meeting with the FDA to finalize plans for the pivotal Phase III trial.
• Submit an application for Fast Track status in 2024.
• Start enrollment in the Phase II TRD trial after the AD Phase II trial finishes patient enrollment.
• Continue enrollment in the Phase I/II trial of INKmune in mCRPC.
• Report data from each cohort of the INKmune mCRPC trial as it becomes available.
• Complete enrollment of the Phase I portion of the INKmune mCRPC trial by September 2024.
• Complete enrollment of the Phase I/II trial of INKmune in mCRPC by 1H25 with top-line data available 6 months later.
• Continue to seek partners for the INB03, XPro and DMD programs.

Key Dates

Keywords

immunotherapy, cancer, Alzheimer's disease, treatment-resistant depression, natural killer cells, TNF, clinical trials, biotechnology, pharmaceutical, drug development, MUC4, neuroinflammation, prostate cancer, orphan drug, regulatory approval